Literature DB >> 27312773

Dramatic differences in susceptibility to l-DOPA-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion.

Francesco Bez1, Veronica Francardo2, M Angela Cenci3.   

Abstract

Mice with striatal 6-hydroxydopamine (6-OHDA) lesions are widely used as a model to study the effects of neurorestorative, symptomatic, or antidyskinetic treatments for Parkinson's disease (PD). The standard praxis is to utilize young adult mice with relatively acute 6-OHDA lesions. However, long post-lesion intervals may be required for longitudinal studies of treatment interventions, and the long-term stability of the model's behavioral and cellular phenotypes is currently unknown. In this study, C57Bl/6J mice sustained unilateral striatal 6-OHDA lesions at approx. 2months of age, and were allowed to survive for 1, 10 or 22months. Another group of mice sustained the lesion at the age of 23months and survived for one month thereafter. Baseline and drug-induced motor behaviors were examined using a battery of tests (utilizing also a novel video-based methodology). The extent of nigral dopamine cell loss was stable across post-lesion intervals and ages. However, a prominent sprouting of both dopaminergic and serotonergic fibers was detected in the caudate-putamen in animals that survived until 10 and 22months post-lesion. This phenomenon was associated with a recovery of baseline motor deficits, and with a lack of dyskinetic responses upon treatment with either l-DOPA or apomorphine. By contrast, mice sustaining the lesion at 23months of age showed a striking susceptibility to the dyskinetic effects of both l-DOPA and apomorphine, which was associated with a pronounced drug-induced upregulation of ∆FosB in the ventrolateral striatum. The results reveal a remarkable compensatory capacity of a damaged nigrostriatal pathway in ageing mice, and how this impacts on the response to dopaminergic therapies for PD.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  6-Hydroxydopamine; Ageing; Mouse; Neuroplasticity; Parkinson's disease

Mesh:

Substances:

Year:  2016        PMID: 27312773     DOI: 10.1016/j.nbd.2016.06.005

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  6 in total

1.  Nanodelivery of Cerebrolysin and Rearing in Enriched Environment Induce Neuroprotective Effects in a Preclinical Rat Model of Parkinson's Disease.

Authors:  C Requejo; J A Ruiz-Ortega; H Cepeda; A Sharma; H S Sharma; A Ozkizilcik; R Tian; H Moessler; L Ugedo; J V Lafuente
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

2.  Late aging-associated increases in L-DOPA-induced dyskinesia are accompanied by heightened neuroinflammation in the hemi-parkinsonian rat.

Authors:  Kathryn Lanza; Amy E Perkins; Terrence Deak; Christopher Bishop
Journal:  Neurobiol Aging       Date:  2019-05-31       Impact factor: 4.673

3.  Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy.

Authors:  Cristina Alcacer; Laura Andreoli; Irene Sebastianutto; Johan Jakobsson; Tim Fieblinger; Maria Angela Cenci
Journal:  J Clin Invest       Date:  2017-01-23       Impact factor: 14.808

Review 4.  Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse.

Authors:  Elisabetta Tronci; Veronica Francardo
Journal:  J Neural Transm (Vienna)       Date:  2017-12-14       Impact factor: 3.575

5.  Evidence for Sprouting of Dopamine and Serotonin Axons in the Pallidum of Parkinsonian Monkeys.

Authors:  Dave Gagnon; Lara Eid; Dymka Coudé; Carl Whissel; Thérèse Di Paolo; André Parent; Martin Parent
Journal:  Front Neuroanat       Date:  2018-05-15       Impact factor: 3.856

6.  Effects of Aging on Levo-Dihydroxyphenylalanine- Induced Dyskinesia in a Rat Model of Parkinson's Disease.

Authors:  Haruo Nishijima; Tamaki Kimura; Fumiaki Mori; Koichi Wakabayashi; Iku Kinoshita; Takashi Nakamura; Tomoya Kon; Chieko Suzuki; Masahiko Tomiyama
Journal:  Front Aging Neurosci       Date:  2021-05-13       Impact factor: 5.750

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.